medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (1)


Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Manzano-Robleda MC, Ornelas-Arroyo V, Barrientos-Gutiérrez T, Méndez-Sánchez N, Uribe M, Chávez-Tapia NC

Idioma: Ingles.
Referencias bibliográficas: 50
Paginas: 46-57
Archivo PDF: 136.77 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guidelines for the screening, care and treatment of persons with hepatitis infection. World Health Organization 2014. Available at: www.who.int/about/licensing/ copyright_form/en/index.html.

  2. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014; 370: 1869-71.

  3. AASLD and IDSA Launch Web-Based Recommendations for Testing, Managing, and Treating HCV. AASLD 2014.

  4. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat 2014; 21: 348-56.

  5. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferManzano- Robleda MC, et al. , 2015; 14 (1): 46-57 56 on/ribavirin obviates a protease inhibitor. Hepatology 2014; 59: 71-7.

  6. Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther 2014; 39: 14-24.

  7. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS One 2014; 9: e94542.

  8. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158: 114-23.

  9. Lawitz EJ, Membreno FE. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects. J Gastroenterol Hepatol 2014; 29 (8): 1574-81 doi: 10.1111/jgh.12632.

  10. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.

  11. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

  12. G.A.W. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Otawa Hospital Reaserch Institute. Available at: http:// www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  13. Thorlund K. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011, p. 1-115.

  14. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.

  15. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.

  16. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.

  17. Sulkowski M. Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. Hepatology 2012; 56: 1144A.

  18. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.

  19. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  20. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  21. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.

  22. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  23. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.

  24. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.

  25. Flamm SL, Lawitz E, Jacobson I, Bourliere M, Hezode C, Vierling JM, Bacon BR, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11: 81-87, e84; quiz e85.

  26. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.

  27. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.

  28. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.

  29. Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, et al. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawaii J Med Public Health 2013; 72: 6-13.

  30. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.

  31. Singh G. The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection. Gastroenterology 2013; 144: S-1136.

  32. Sulkowski M. Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011; 54: 594.

  33. Karino Y. Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy. J Hepatol 2013; 58: S338.

  34. Lawitz E. Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients. Hepatology 2012; 56: 1144A.

  35. Purohit T. Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor. Gastroenterology 2013; 144: S983-S984.

  36. Asahina Y. Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C. J Hepatol 2013; 58: S321.

  37. Ogawa E. Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin. J Hepatol 2013; 58: S-632.

  38. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, Perner D, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-7.

  39. Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela- Nogueira CA, Urmenyi TP, Tanuri A, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 2013; 10: 57.

  40. Thomas XV. Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing. J Hepatol 2011; 54: S490-S491.

  41. Pinson P. Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients. J Hepatol 2012; 56: S614.

  42. Volpe JM. Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Hepatology 2012; 54: 1144A.

  43. Velazquez C. Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre. J Hepatol 2013; 58: S632.

  44. Messina E. Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain. J Hepatol 2013; 58: S632.

  45. Galmozzi. Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin. Dig Liver Dis 2013; 45: S54.

  46. Cento V. HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients. J Hepatol 2013; 58: S632.

  47. Cento V. Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir. J Hepatol 2013; 58: S632.

  48. Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. Viruses 2012; 4: 3281-302.

  49. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.

  50. Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013; 27: 2485-8.




2020     |     www.medigraphic.com